Barclays Maintains an 'Equalweight' on Teva Pharma (TEVA); Adjusting Estimates After Business Update
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Price: $39.35 -2.14%
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade TEVA Now!
Barclays maintains an 'Equalweight' on Teva Pharma (NASDAQ: TEVA) price target of $42.00.
Analyst, Douglas D. Tsao, said, "We are lowering our FY12 EPS estimate to $5.33 (from $5.57) after the company lowered guidance yesterday morning as part of a business update provided by newly-minted CEO Jeremy Levin. The timing was a bit of a surprise, but the takedown in expectations was largely anticipated after TEVA's 1Q showed softness. Management lowered its '12 EPS range to $5.30-$5.40 (cons $5.59) versus the previous $5.48-$5.68 (consensus at $5.59), with '12 revenues declining to $20Bn-$21bn versus previous $22bn."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.69 yesterday, with a 52 week range of $35.00-$51.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Douglas D. Tsao, said, "We are lowering our FY12 EPS estimate to $5.33 (from $5.57) after the company lowered guidance yesterday morning as part of a business update provided by newly-minted CEO Jeremy Levin. The timing was a bit of a surprise, but the takedown in expectations was largely anticipated after TEVA's 1Q showed softness. Management lowered its '12 EPS range to $5.30-$5.40 (cons $5.59) versus the previous $5.48-$5.68 (consensus at $5.59), with '12 revenues declining to $20Bn-$21bn versus previous $22bn."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.69 yesterday, with a 52 week range of $35.00-$51.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Benchmark Boosts PT on R.R. Donnelley (RRD)
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Microsoft (MSFT) Rally is Over, Says Barclays
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
